What people report
SS-31 reviews: what people report
Read 20 people, 2 sitesPublished by PepVault
Of the 20 people whose SS-31 write-ups we read, 16 describe a change they wanted (9 more energy or strength; 3 clearer thinking, memory or mood), 2 noticed nothing and 5 describe something unwanted.
What people report
16 of the 20 people describe at least one change they wanted. Each bar counts the people who named anything in that group, once each, out of all 20; the line under it says what they named, and how many named it. 6 of them took SS-31 alongside other peptides at the same time.
What went wrong or did nothing
5 of the 20 people describe something they didn’t want, and 2 noticed nothing at all.
Your report
Taken SS-31? What did you notice?
One tap to start. About 30 seconds, no account.

When people say it begins
0 of the 20 people say when they first noticed something; 20 don’t.
What people took it for
2 of the 20 people say what they took it for; 18 don’t.
How it’s thought to work
Shown in people
SS-31, or elamipretide, is a small lab-made peptide that settles on cardiolipin, a fat in the inner wall of the mitochondria, the cell’s power plants. In cells and animals it steadied their energy output and cut the harmful oxygen they leak. It is approved in the US for Barth syndrome, a rare inherited disease of the mitochondria; in larger trials in other mitochondrial and heart diseases it mostly missed its goals.
Sources: Karaa et al., 2023: MMPOWER-3, a mitochondrial muscle disease; Roshanravan et al., 2021: one infusion in older adults
What studies show
Our research section has 14 study pages on SS-31: 11 in people and 3 in mice.
The largest trial gave 218 people with a genetic muscle disease of the mitochondria a daily shot of elamipretide or a dummy shot for 24 weeks; their walking distance and fatigue did not improve.
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trial
- SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial
- SS-31: wearable data grouped responders with 100% accuracy
- SS-31: no 12-week benefit, walk gains by 36 weeks open-label
- SS-31 raised muscle ATP capacity after one dose in older adults
- SS-31: walk distance rose with dose in 5-day MMPOWER trial
- SS-31: less kidney hypoxia after renal artery stenting in pilot
- SS-31 did not significantly cut infarct size in EMBRACE STEMI
- SS-31: 96.1 m longer 6-minute walk at 168 weeks in TAZPOWER
- SS-31 (elamipretide) lowered blood HtrA2 after STEMI heart attack
- SS-31: 79.7 m better walk test vs untreated in Barth syndrome
- SS-31 aided functional recovery after spinal cord injury in mice
- SS-31 partly undid age-related muscle phosphorylation in old mice
- SS-31 eased LPS-induced learning and memory problems in mice
- SS-31 in the library: how it works, half-life and evidence
- Is SS-31 legal? FDA, DEA and WADA status
- SS-31 dose guide
Where the reports run ahead of the studies
9 of the 20 people describe more energy or stamina, many of them healthy and taking it for health. The trials tested it in people with rare mitochondrial diseases and heart or kidney problems; in healthy older adults one infusion raised the muscles’ peak energy output right after, not a week later, and did not lessen fatigue (PubMed, searched November 19, 2026).
Where the reports come from
20 people on 7 pages across 2 sites, written from October 2025 to October 2026. Read on November 19, 2026.
The largest single site, the Peptide Critic forum, gave 15 of the 20.
Peptide Critic, which runs its forum, also runs a shop on its own site that sells injection pens and supplies, not peptides.
Many people here took SS-31 with MOTS-c and NAD+ as one “mitochondria stack”, at very different doses, and several say they felt little until they raised it.
- Peptide Critic forum, a thread for people taking SS-31 for the first time: 8 people
- rapamycin.news forum, the SS-31 thread: 4 people
- Peptide Critic forum, a thread on SS-31 doses: 3 people
- Peptide Critic forum, the SS-31 protocol thread: 2 people
- Peptide Critic forum, a thread on MOTS-c and blood pressure: 1 person
- Peptide Critic forum, a thread on whether MOTS-c is needed with SS-31: 1 person
- rapamycin.news forum, the peptides and bioregulators thread: 1 person
Read and not counted
- A Peptide Critic forum staff member’s posts: The same account posts the forum’s vendor sales roundups, and the site runs its own store: the seller’s side of the counter, so not counted.
- A rapamycin.news member who supplies peptides to clients: Posts at length about the dosing he and his family and clients use: the seller’s side of the counter, so not counted.
- Posts that started SS-31 with no outcome yet: Plans and first days; nothing noticed was said.
- Reports about someone else (a wife, a friend’s wife, a partner): Second-hand; only a person’s own report counts.
- Posts about vendors, testing, prices and dosing with no effect named: Most posts in these threads; nothing noticed was said.
- Reddit and X: Not part of this count.
How we counted
We read every open write-up we could find by people who took SS-31, on its own page, and counted each person once however often they posted, including those who noticed nothing. Sellers, clinics, shop reviews and anyone who earns on a sale are not counted, and neither is a search result’s snippet; the list above names what we read and left out. Write-ups lean positive, because people who notice nothing rarely write about it and expecting an effect can produce one.
Spot an error? feedback@pepvault.app. How we research. This page reports what people say; it is not medical advice.